# Drug-induced nonautoimmune hemolytic anemia

**Drug-induced nonautoimmune hemolytic anemia** is hemolytic anemia caused by a medication through mechanisms other than a true autoantibody against the patient's own red blood cells. It covers two broad groups: immune hemolysis driven by drug-dependent antibodies or by nonimmunologic protein adsorption, and nonimmune hemolysis from oxidative damage to red cells (as in glucose-6-phosphate dehydrogenase deficiency) or from drug-induced thrombotic microangiopathy<sup>[1](https://pubmed.ncbi.nlm.nih.gov/28648734/)</sup>. The condition is rare, with an estimated incidence of about 1 case per million of the population<sup>[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC3654623/)</sup>, but it is potentially lethal and is easily mistaken for warm autoimmune hemolytic anemia or a hemolytic transfusion reaction<sup>[3](https://pubmed.ncbi.nlm.nih.gov/25247622/)</sup>.

| Key fact | Detail |
|---|---|
| Frequency | Estimated incidence of about 1 per million of the population; drug-induced immune hemolytic anemia makes up about 10% of cases in series of patients with autoimmune hemolytic anemia<sup>[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC3654623/)</sup><sup> • </sup><sup>[4](https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.14654)</sup> |
| Implicated drugs | 125 drugs had reasonable evidence of causing drug-induced immune hemolytic anemia as of a 2007 review; a 2025 review cites around 140 medications<sup>[5](https://www.sciencedirect.com/science/article/pii/S0268960X10000275)</sup><sup> • </sup><sup>[6](https://journals.viamedica.pl/journal_of_transfusion_medicine_and_hemostasis/article/download/106171/84153)</sup> |
| Leading drugs | Antimicrobials, especially cefotetan, ceftriaxone, and piperacillin; piperacillin was reported in 2014 as the most commonly encountered cause<sup>[5](https://www.sciencedirect.com/science/article/pii/S0268960X10000275)</sup><sup> • </sup><sup>[7](https://pubmed.ncbi.nlm.nih.gov/25247621/)</sup> |
| Main mechanisms | Drug-dependent antibodies (immune complex or penicillin type), nonimmunologic protein adsorption, oxidative hemolysis in G6PD deficiency, and drug-induced thrombotic microangiopathy<sup>[8](https://www.sciencedirect.com/science/article/pii/0002934375906063)</sup><sup> • </sup><sup>[1](https://pubmed.ncbi.nlm.nih.gov/28648734/)</sup> |
| Diagnosis | Direct antiglobulin test (DAT) typically positive; a drug metabolite rather than the parent drug may be responsible, complicating diagnosis<sup>[9](https://www.ncbi.nlm.nih.gov/sites/books/NBK606096/?report=classic)</sup> |
| Treatment | Stop the causative drug; prednisone may be added to suppress the immune response; transfusion in severe cases<sup>[10](https://medlineplus.gov/ency/article/000578.htm)</sup> |
| Prognosis | Good if the causative drug is identified and stopped; death is rare but has been reported, particularly in children with hemolysis caused by cefotetan and ceftriaxone<sup>[11](https://www.orpha.net/en/disease/detail/90037?mode=name&name=Drug-induced+AIHA)</sup> |

## Mechanisms

Drug-induced hemolytic anemia takes three main forms: oxidative damage to vulnerable erythrocytes, drug-induced thrombotic microangiopathy, and immune-mediated hemolytic anemia<sup>[1](https://pubmed.ncbi.nlm.nih.gov/28648734/)</sup>.

**Drug-dependent antibodies.** In the immune complex mechanism, phenacetin, quinidine, and similar drugs combine with the antibody directed against the drug; this complex then binds to erythrocytes, typically activating complement and producing abrupt hemolysis within blood vessels<sup>[8](https://www.sciencedirect.com/science/article/pii/0002934375906063)</sup>. Quinine-induced hemolysis is the prototype of this mechanism, in which the drug induces IgM antibody production<sup>[12](https://www.aafp.org/afp/2004/0601/p2599.pdf)</sup>. In the penicillin-type (hapten) mechanism, high-dose penicillin coats normal red cells in vivo, and in some patients a high-titer IgG anti-drug antibody develops that reacts with the coated cells; red cell destruction is then primarily extravascular<sup>[8](https://www.sciencedirect.com/science/article/pii/0002934375906063)</sup><sup> • </sup><sup>[12](https://www.aafp.org/afp/2004/0601/p2599.pdf)</sup>.

**Nonimmunologic protein adsorption.** Nonimmunologic protein adsorption. In a small fraction of patients, cephalosporins yield direct antiglobulin test results that are positive, doing so either through a mechanism identical to that of penicillins or by altering the red cell membrane so that serum proteins adhere nonimmunologically; instances of hemolytic anemia arising this way have been reported only seldom.<sup>[8](https://www.sciencedirect.com/science/article/pii/0002934375906063)</sup> Nonimmunologic protein adsorption is independent of antibody production but may also cause immune hemolytic anemia<sup>[13](https://pubmed.ncbi.nlm.nih.gov/25247618/)</sup>.

**Oxidative hemolysis.** Oxidant drugs and their metabolites, such as dapsone hydroxylamine and 5-hydroxyprimaquine, generate reactive oxygen species that overwhelm the red cell's defenses, damaging the membrane and leading to hemolysis; susceptibility is highest in glucose-6-phosphate dehydrogenase (G6PD) deficiency<sup>[1](https://pubmed.ncbi.nlm.nih.gov/28648734/)</sup><sup> • </sup><sup>[14](https://pmc.ncbi.nlm.nih.gov/articles/PMC12343164/)</sup>. Primaquine, [phenazopyridine](https://www.edgepedia.org/phenazopyridine), nitrofurantoin, and certain sulfas have been associated with this kind of hemolysis<sup>[15](https://pmc.ncbi.nlm.nih.gov/articles/PMC2778502/)</sup>.

**Thrombotic microangiopathy.** Drug-induced thrombotic microangiopathy is a nonimmune form in which fragmentation of red cells produces schistocytes on the blood smear; it belongs to the same differential group as thrombotic thrombocytopenic purpura and hemolytic uremic syndrome<sup>[1](https://pubmed.ncbi.nlm.nih.gov/28648734/)</sup><sup> • </sup><sup>[16](https://www.aafp.org/pubs/afp/issues/2018/0915/p354.pdf)</sup>.

## Which drugs are involved

The most common drugs causing drug-induced immune hemolytic anemia are antimicrobials, such as [cefotetan](https://www.edgepedia.org/cefotetan), ceftriaxone, and piperacillin, which are associated with drug-dependent antibodies<sup>[5](https://www.sciencedirect.com/science/article/pii/S0268960X10000275)</sup>. The spectrum has shifted over time: in the 1970s the most common drugs were methyldopa and penicillin, while in the 2000s they were cefotetan and ceftriaxone<sup>[17](https://www.sciencedirect.com/science/article/pii/S0037196305000570)</sup>. A 2014 update from a specialist laboratory reported piperacillin as the most commonly encountered cause<sup>[7](https://pubmed.ncbi.nlm.nih.gov/25247621/)</sup>. Case series have found that NSAIDs account for less than 15% of cases, with the majority caused by beta-lactam antibiotics such as cephalosporins and penicillins<sup>[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC3654623/)</sup>. The most frequently reported cases involve antibiotics, non-steroidal anti-inflammatory drugs, and antineoplastic agents<sup>[6](https://journals.viamedica.pl/journal_of_transfusion_medicine_and_hemostasis/article/download/106171/84153)</sup>.

By contrast, drug-independent antibodies, which are serologically indistinguishable from warm autoantibodies, are the mechanism behind the classic autoimmune form of drug-induced hemolytic anemia; the most common drug causing that form is fludarabine<sup>[5](https://www.sciencedirect.com/science/article/pii/S0268960X10000275)</sup>. Alpha-methyldopa is the classic example of a drug causing true autoimmune hemolytic anemia<sup>[8](https://www.sciencedirect.com/science/article/pii/0002934375906063)</sup>.

## History

Drugs were first suspected as a cause of immune hemolytic anemia in 1953, when Snapper described a patient who developed pancytopenia with hemolytic anemia and a positive direct antiglobulin test after taking mephenytoin<sup>[5](https://www.sciencedirect.com/science/article/pii/S0268960X10000275)</sup>. Harris documented the first carefully worked-out case, involving stibophen, a drug used to treat schistosomiasis: the patient had tolerated a course ten years earlier, then developed acute intravascular hemolysis during a second course, and the serum reacted with red cells only when the drug was present<sup>[5](https://www.sciencedirect.com/science/article/pii/S0268960X10000275)</sup>. In 1967, Dausset and Contu found only 34 published cases due to 15 drugs; by 1980 about 33 drugs were known, by 1989 over 50, and by 2007 the list had grown to 125 drugs with reasonable evidence<sup>[5](https://www.sciencedirect.com/science/article/pii/S0268960X10000275)</sup>. A 1975 review estimated that drug administration caused 16 to 18 percent of cases of acquired immune hemolytic anemia<sup>[8](https://www.sciencedirect.com/science/article/pii/0002934375906063)</sup>.

## Diagnosis

The direct antiglobulin test (DAT, or direct [Coombs test](https://www.edgepedia.org/coombs-test)) is typically positive in drug-induced immune hemolytic anemia, but occasionally a drug metabolite rather than the parent drug itself is responsible, which complicates diagnosis<sup>[9](https://www.ncbi.nlm.nih.gov/sites/books/NBK606096/?report=classic)</sup>. Drug-dependent antibodies are investigated by testing drug-treated red blood cells or by testing untreated red cells in the presence of a solution of the drug; drug-independent antibodies react without drug present and cannot be distinguished serologically from warm autoantibodies<sup>[3](https://pubmed.ncbi.nlm.nih.gov/25247622/)</sup><sup> • </sup><sup>[13](https://pubmed.ncbi.nlm.nih.gov/25247618/)</sup>. An investigation for a drug antibody is warranted when a patient has definitive evidence of immune hemolysis, other more common causes have been excluded, and there is a good temporal relationship between drug administration and the hemolytic event<sup>[13](https://pubmed.ncbi.nlm.nih.gov/25247618/)</sup>.

Because serologic results can mimic those of autoimmune hemolytic anemia or hemolytic transfusion reactions, the condition may go undetected in some cases<sup>[3](https://pubmed.ncbi.nlm.nih.gov/25247622/)</sup>. Acute intravascular hemolysis can be mistaken for a hemolytic transfusion reaction or acute sepsis, so the drug history should include perioperative antibiotics and over-the-counter analgesia such as NSAIDs<sup>[4](https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.14654)</sup>. Once a formal diagnosis of hemolytic anemia follows the administration of a drug, experts advise a systematic evaluation of whether an adverse drug reaction is plausible, considering the timing of events, epidemiological information, objective evidence if it exists, and the exclusion of causes unrelated to drugs<sup>[1](https://pubmed.ncbi.nlm.nih.gov/28648734/)</sup>.

## Treatment and outcome

Finding the drug causing the problem and stopping it is the first approach to therapy<sup>[5](https://www.sciencedirect.com/science/article/pii/S0268960X10000275)</sup>. Stopping the medicine may relieve or control the symptoms; prednisone may be prescribed to suppress the immune response, special blood transfusions may be needed for severe symptoms, and a folic acid supplement is usually given<sup>[10](https://medlineplus.gov/ency/article/000578.htm)</sup>. In the drug-independent (autoimmune) form, steroids are added to drug discontinuation<sup>[2](https://pmc.ncbi.nlm.nih.gov/articles/PMC3654623/)</sup>.

The prognosis is good if the causative drug is identified and stopped<sup>[11](https://www.orpha.net/en/disease/detail/90037?mode=name&name=Drug-induced+AIHA)</sup>. Death from severe anemia is rare, but it has been reported, particularly in children with hemolysis caused by cefotetan and ceftriaxone<sup>[10](https://medlineplus.gov/ency/article/000578.htm)</sup><sup> • </sup><sup>[11](https://www.orpha.net/en/disease/detail/90037?mode=name&name=Drug-induced+AIHA)</sup>.

## References

1. [Renard D, Rosselet A (2017). Drug-induced hemolytic anemia: Pharmacological aspects. Transfusion Clinique et Biologique.](https://pubmed.ncbi.nlm.nih.gov/28648734/)
2. [Barbaryan A, et al. (2013). Ibuprofen-Induced Hemolytic Anemia. Case Reports in Hematology.](https://pmc.ncbi.nlm.nih.gov/articles/PMC3654623/)
3. [Arndt PA (2014). Drug-induced immune hemolytic anemia: the last 30 years of changes. Immunohematology.](https://pubmed.ncbi.nlm.nih.gov/25247622/)
4. [BCSH (2016). Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia. British Journal of Haematology.](https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.14654)
5. [Garratty G (2010). Immune hemolytic anemia associated with drug therapy. Blood Reviews.](https://www.sciencedirect.com/science/article/pii/S0268960X10000275)
6. [Mazur U, Kunysz M, Pacyna K (2025). Drug-induced immune hemolytic anemia — the influence of selected drugs on immunohematology testing. Journal of Transfusion Medicine and Hemostasis.](https://journals.viamedica.pl/journal_of_transfusion_medicine_and_hemostasis/article/download/106171/84153)
7. [Arndt PA, Garratty G (2014). Drugs that have been shown to cause drug-induced immune hemolytic anemia or positive direct antiglobulin tests: some interesting findings since 2007. Immunohematology.](https://pubmed.ncbi.nlm.nih.gov/25247621/)
8. [Garratty G, Petz LD (1975). Drug-induced immune hemolytic anemia. American Journal of Medicine.](https://www.sciencedirect.com/science/article/pii/0002934375906063)
9. [Laboratory Evaluation of Immune Hemolytic Anemias. StatPearls, NCBI Bookshelf.](https://www.ncbi.nlm.nih.gov/sites/books/NBK606096/?report=classic)
10. [Drug-induced immune hemolytic anemia. MedlinePlus Medical Encyclopedia.](https://medlineplus.gov/ency/article/000578.htm)
11. [Drug-induced autoimmune hemolytic anemia. Orphanet.](https://www.orpha.net/en/disease/detail/90037?mode=name&name=Drug-induced+AIHA)
12. [Hemolytic Anemia. American Family Physician (2004).](https://www.aafp.org/afp/2004/0601/p2599.pdf)
13. [Leger RM, Arndt PA, Garratty G (2014). How we investigate drug-induced immune hemolytic anemia. Immunohematology.](https://pubmed.ncbi.nlm.nih.gov/25247618/)
14. [Molecular Mechanisms of Drug-Induced Hemolysis in G6PD Deficiency: Mechanistic Insights. PMC.](https://pmc.ncbi.nlm.nih.gov/articles/PMC12343164/)
15. [Mintzer DM, Billet SN, Chmielewski L (2009). Drug-Induced Hematologic Syndromes. Advances in Hematology.](https://pmc.ncbi.nlm.nih.gov/articles/PMC2778502/)
16. [Hemolytic Anemia: Evaluation and Differential Diagnosis. American Family Physician (2018).](https://www.aafp.org/pubs/afp/issues/2018/0915/p354.pdf)
17. [Arndt PA, Garratty G (2005). The Changing Spectrum of Drug-Induced Immune Hemolytic Anemia. Seminars in Hematology.](https://www.sciencedirect.com/science/article/pii/S0037196305000570)

---
*Topic: Encyclopedia › Life and health › Human health and medicine › Diseases and injuries › Cardiovascular and blood conditions › Blood disorders (hematologic conditions) › Anemias › Hemolytic anemias › Drug-induced hemolytic anemia*

*Initially written Sep 17, 2026 · Reviewed: Oct 21, 2026 · Edited: Oct 11, 2026; Oct 15, 2026; Oct 21, 2026 · Last review: Oct 21, 2026*

*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*

License: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license
